These data suggest that Bcl-2 inhibition is effective against lymphoid malignancies in which Bcl-2 is a key oncogenic driver [41], but that this inhibition alone is not as effective in the treatment of breast cancer. This evidence concerns the gene BCL2 and breast carcinoma.